Verastem Inc (VSTM)
Business numbers score is on the low side; smart-money score is below the middle; price trend score is near the top of its range.
VSTM scores higher than 70% of the 1,101 tickers we compare it with (Health Care).
As of 9 October 2026, Verastem Inc (VSTM) scores 51 out of 100 on the Market Census six-factor composite, which puts it at the Average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 1.20× 30-day average
- 52-week range
- 3.43 – 10.82
- Market cap
- $529.00M
- Earnings date
- 2 Nov 2026
- Volume
- 2,970,138
- Avg. volume (30d)
- 2,465,637
- Open
- 8.12
- Previous close
- 8.11
- Day's range (regular session)
- 7.98 – 8.58
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 0.58
- P/E (TTM)
- —
- EPS (TTM)
- -2.46
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
Premium data held for VSTM
- 6 SEC Form 4 insider transactions in the last 90 daysPremium
Counts of rows Market Census holds for VSTM. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans
What the score says about VSTM right now
Verastem Inc (VSTM) currently scores 51/100 on the Market Census six-factor composite, at the Average score level. VSTM is +3.33% on the day and +8.38% over five sessions as of the most recent tick. Average sits in the middle. The good and the bad in VSTM's data roughly balance out right now. VSTM's strongest factor is price trend at 89/100 — a very strong read on which way the price has been going. The weakest factor is company finances at 4/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See VSTM in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent VSTM news
Latest headlines that name Verastem, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo
- Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026Yahoo
- Verastem Oncology To Present Data From New Molecular Profiling, Tumor Biomarker Analysis Of Phase 2 RAMP 201 Clinical Trial Of Avutometinib Plus Defactinib In Patients With Recurrent LGSOC, At IGCS 2026Benzinga
- Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian CancerYahoo
- Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global MeetingYahoo
We hide 8 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to VSTM’s 51, all within 1 point.
Sorted by closeness to VSTM’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.